{"name":"Immune-Onc Therapeutics","slug":"immune-onc-therapeutics","ticker":"","exchange":"","domain":"immuneonc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPdEc0OUhJcFlVcGtvQllhQXkxd29xRnllZVRMRnVPaEdqbFoyOVIwOXk3eEs4UkpQSmhLM0ZzaXJWdjAzdmdFSHdzNnJVcjFVck53bUhqQnhoQS1lcm4zM3FFTzF1YUdDSTFLVjNuaDhLRlFlakRYc19JX3hFeDJDbGUybjNXdXdtMU5vUTZhZ204MXNnX0M5Um1IcnRDZlBnZzg0S2Q2cktVYVlnOGc?oc=5","date":"2026-03-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Targeted therapies to join chemo as oncology treatment backbone - Pharmaceutical Technology","headline":"Targeted therapies to join chemo as oncology treatment backbone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdFRBVkg2R0Z2WTZDdlZxTVZ1QTQ1OHh4Y18xMDNydmNCLWh4TUstdlFJOXJuVDBWSzFyQmNtYThTLXYtZ0lkWHN0WkVVQXU3RFMyRmpUZ1JNaUd5NThTQ1pTSDR3MmM1bHFWa2xUNjdUR2dMUXpsMkRZLXZXci05Sno0aGh4UmRuUkJmVVVKVURodmp4dWM5NmhhTTNVbjFaTFpVOXp1Y3AwT0J2NFNMSzliR1g3MzJHOElsbWtHRjdIelZ2?oc=5","date":"2026-02-10","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals - Genetic Engineering and Biotechnology News","headline":"Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - Nature","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWk5QY1A2c0Ryc0dobWlGYk1rdUZpQnVNeXQ4NWh2RENmMXh2UjNzcXJXU1piVEstcElUSk82Q2ZXUFhDaHo4SE1uamJBdDJ5LWFoTHZ2UUNTdFB0b3ZuNzUxaXlyMVU3SnFobTdlOFBwZzRrTVlJVHZVV2M1UTZSWThfMngtS1pFRVJr?oc=5","date":"2025-12-04","type":"trial","source":"Yahoo Finance","summary":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Yahoo Finance","headline":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Dom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9vMGJlalo4NDJRbFpXaTlrdDRVallDTzZCY3FKSU94RHdJSHBSY001WjY4SzRZYjFvYlBYb015M2xkU3FvMjJvRFc2MFFVMG91eTIwZzNfc285SzhWZm9mVkFQZXRqbTladElXTThwMlFoSklXU1dFVG5ob2E?oc=5","date":"2025-12-02","type":"pipeline","source":"Straits Research","summary":"Oncology Based Preclinical CRO Market Size, Share & Growth Report by 2034 - Straits Research","headline":"Oncology Based Preclinical CRO Market Size, Share & Growth Report by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONUcyZkZtLVFSSWFpdGhncGlEYXF3OVZNV0lrMzB0M1dKNlhQUHFuLXZfT1V4NGdMSnV0UC1VektMVFA0SV8wQmd1LWxFTDZlZ2FlWlVHY3hYdjlEbEtIM3ctX2NqbHdkaTBpYnUwODdVTjNPR0xjeTFjTnZZejhVMHVnQ3JRcEoyS3lOSUtlcFBhRGc?oc=5","date":"2025-11-06","type":"pipeline","source":"Insightace Analytic","summary":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Immuno-Oncology Cell Therapy Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBtcXRkVXRSenlXZFdxUWR1V0drMWlTeUNfUVBQRERlUV9qeVdoTEo3LXhyRWRBYVdxZ2VocVMxTVB2cm5JWVE3Q1ZscUJIdHlKSEdQaU5DSDVqOUctTE5fVWc0b0tCVm16aGR1S3Z1ODY1cGV6?oc=5","date":"2025-09-30","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Top pharmaceuticals of H1 2025: Ozempic and Mounjaro enter top three - drugdiscoverytrends.com","headline":"Top pharmaceuticals of H1 2025: Ozempic and Mounjaro enter top three","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFA1ZTI5U1hUWVBCbzQ1OGhlT1pFU1JvWHBuZGQ4XzFIdDhsQm9UWlhPZkN1U2FyUDdKWjQ4d2c1TURwTEJIN201UTNDdHo0TmE2MWFYbVlvYmdJUXFZX2U3Ty02OA?oc=5","date":"2025-08-27","type":"regulatory","source":"Wiley Online Library","summary":"American Journal of Hematology | Blood Research Journal - Wiley Online Library","headline":"American Journal of Hematology | Blood Research Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8tNm9uclRjeTJjcEpUbmhLTHR4SlY5TTREWlBmbTdLaU9FSkxZQ19yY1NNRW1SZVdoZkU4OVJtTnBldzFvU3ljYjEyMHRRV2FCR0dWQ09LNFNqQkswTnZmWlU3aDNjbFdvRGtlaU15b2NsaWViYjlMMzNmOA?oc=5","date":"2025-07-24","type":"trial","source":"globaldata.com","summary":"Immuno-oncology: Strategic Intelligence - globaldata.com","headline":"Immuno-oncology: Strategic Intelligence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQN2wzNFdHTDNla2x0M19VRTh3U3BPdzBjZGZIcU1XeWxlbnBMRzd4Q1N3U2dzcmNjS0tJMlFOa1N1YkxEWElaZWw4aFNLS2Y3MTY1LWdmUVdSaXdKdmc4cDY3WHNJSzFiSzNHbUx3SkpxUWtyVWYtMDQyUDJqSHVlYjcxb1VrcmVVc3FPXzRrZDc3Rmt0Wkp6cmFsSkwwMGl5U3UzS1k3d1hwZnBU?oc=5","date":"2025-06-27","type":"pipeline","source":"statnews.com","summary":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress - statnews.com","headline":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5hV1g5cGtrZ3prdzVobXgySFpNZDRNTTg5dTJnbV9sSmR3RWZ6MF9MbVJmQUZMTTNqRzFWU0FJckR1UGJqdnFCZ3B3WHpaakhxYkVkNnVtekUtbUk?oc=5","date":"2025-05-07","type":"pipeline","source":"ASCO Publications","summary":"One Step Ahead: Preventing Tumor Adaptation to Immune Therapy - ASCO Publications","headline":"One Step Ahead: Preventing Tumor Adaptation to Immune Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFB4eFYxTnJicTZxb0FaYmc3WDNBaU1mZHk1MnkwS2ROTk05eTNDUVU0NVpxNm41LVY5WWNVRzlkMWF0YlAxM3lyM1A1dV9ENjdHaHI0QjRMZmplN2lxdkk1NEhGejV2dXJIU21J?oc=5","date":"2025-02-28","type":"trial","source":"Clinical Trials Arena","summary":"Immune-Onc doses first subject in trial of IO-108 for HCC - Clinical Trials Arena","headline":"Immune-Onc doses first subject in trial of IO-108 for HCC","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}